Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche flu drug speeds relief from symptoms in at-risk patients

Roche said a late-stage clinical trial has shown the Swiss drugmaker’s influenza drug baloxavir marboxil significantly sped time to relief for patients highly vulnerable to serious complications.

Read More »

Pfizer bets on biotech flu vaccine in BioNTech alliance

Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.

Read More »

Roche Q2 2018 Financials: “Firing on All Cylinders”

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.

Read More »

Roche touts new flu drug

Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.

Read More »

FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza

The U.S. FDA accepted a New Drug Application and granted Priority Review for Genentech’s baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older.

Read More »

Statement from FDA Commissioner Scott Gottlieb, M.D. on the efficacy of the 2017-2018 influenza vaccine

Seasonal flu has been widespread in 2018, impacting millions of people across the country. It has been an especially challenging season, with high rates of hospitalization for both influenza and its complications, which include pneumonia and the exacerbation of chronic conditions such as asthma and congestive heart failure. Many schools have closed in an attempt to control the spread of the illness and doctor’s offices are packed with patients seeking diagnosis and antiviral treatment.

Read More »

Germany’s CureVac wins new vaccine funding from Gates Foundation

German biotech firm CureVac secured more financial backing for vaccine development projects from its investor the Bill & Melinda Gates Foundation, working on jabs to prevent malaria and influenza.

Read More »

Google venture arm backs UK universal flu vaccine company

A private British company is developing a vaccine that would be the first in the world to fight all types of flu.

Read More »

Visterra Inks $1B Deal With Vir Biotechnology

Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.

Read More »

Oxford team to test universal flu vaccine

A seasonal flu vaccine that would be the world’s first to fight all types of the virus will be tested in a two-year study involving 2,000+ patients by Oxford researchers.

Read More »

Provention Bio and Johnson & Johnson Ink Deal

Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.

Read More »

J&J Plans 10 Blockbuster Approvals by 2021

In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.

Read More »

GSK files for new Fluarix Quadrivalent indication

GlaxoSmithKline announces U.S. regulatory submission seeking expanded indication for Fluarix Quadrivalent (Influenza Vaccine) for infants 6 months and older.

Read More »

USDA has $80 million-$90 million to fight bird flu

The U.S. Department of Agriculture has $80 million to $90 million left over from the last major outbreak of bird flu to fight any new discoveries of the virus, the department’s chief veterinary officer said.

Read More »

U.S. reports low pathogenic bird flu outbreak in Wisconsin: OIE

The United States reported an outbreak of avian flu on a farm in Wisconsin, the second in the country in less than a week although the virus found this time is considered less virulent, the World Organisation for Animal Health (OIE) said.

Read More »

Britain detects bird flu on premises in eastern England

Britain said it had detected bird flu on premises in eastern England during routine checks carried out following the confirmation of the virus at a nearby farm.

Read More »

In China, consumers seem to shrug off deadly bird flu outbreak

Four years ago, a bird flu outbreak in China killed at least three dozen people, triggered mass poultry culling, put masks on millions of Chinese faces and hammered shares in fast food and travel companies. During the winter of 2016/2017, more than 100 people have died, but few birds have been slaughtered, there are few masks on the streets and little sign of any consumer reaction, let alone the panic seen in 2013.

Read More »

Generic copy of Roche flu pill Tamiflu hits U.S. market

The first generic copy of Roche’s top-selling flu pill Tamiflu hit the U.S. market, marking a further step in the Swiss drugmaker’s enforced evolution to reliance on a new wave of blockbuster medicines.

Read More »

Novavax Stayin’ Alive After Shares Crater on Flunked Phase III

Shares of Novavax plummeted more than 82 percent after the company released data that its Phase III trial for its RSV F Vaccine for older adults did not meet its goals, failing to demonstrate “vaccine efficacy.”

Read More »

U.S. CDC spurns AstraZeneca nasal flu vaccine

AstraZeneca said it would take an $80 million writedown on stocks of its intranasal flu vaccine Flumist Quadrivalent after U.S. health authorities decided they would not use the product.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom